Global Stem Cell Therapy Market 2017-2021

  • ID: 4070557
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • bluebird bio
  • Daiichi Sankyo
  • Kiadis Pharma
  • Pluristem Therapeutics
  • Taiwan Bio Therapeutics
  • MORE
Stem cell therapy is the use of stem cells for the treatment or prevention of a disease or condition. Bone marrow transplant is the widely-used stem cell therapy, followed by therapies derived from umbilical cord blood. Research is being undertaken to develop various sources (such as cord blood cells, bone marrow, and skin) for stem cells, and to apply them to various disorders like neurodegenerative diseases and conditions such as heart disease, diabetes, and other conditions.

The analysts forecast the global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global stem cell therapy market for 2017-2021. To calculate the market size, the report considers the sales of stem cell therapy products/segments in the market.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Holostem Advanced Therapies
- JCR Pharmaceuticals
- Organogenesis
- Osiris Therapeutics
- Vericel

Other prominent vendors
- AbbVie
- American CryoStem
- AM-Pharma
- Anterogen
- apceth Biopharma
- Astellas Pharma
- Athersys
- Baxter International
- Beike Biotechnology
- BIOTIME
- bluebird bio
- Bristol-Myers Squibb
- BrainStorm Cell Therapeutics
- Brainxell
- Caladrius Biosciences
- Cellular Biomedicine Group
- Cellular Dynamics International (a subsidiary of Fujifilm)
- Cesca Therapeutics
- CHA Biotech
- Chugai Pharmaceutical
- Citospin
- Corestem
- Cytori Therapeutics
- Daiichi Sankyo
- Fujifilm
- Gamida Cell
- Global Stem Cells Group
- Grupo Ferrer Internacional
- GlaxoSmithKline
- Hemostemix
- Histocell
- International Stem Cell
- Ivy Institute of Stem Cells
- Japan Regenerative Medicine
- Kangstem Biotech
- Kiadis Pharma
- Laboratorios Salvat
- MEDIPOST
- Mesoblast
- Nuo Therapeutics
- Opsis Therapeutics
- Osiris Therapeutics
- Pharmicell
- Pluristem Therapeutics
- Promethera Biosciences
- Q Therapeutics
- ReNeuron
- RHEACELL
- Salus Medical Solutions
- Sangamo Therapeutics
- Shire
- Steminent Biotherapeutics
- Sumitomo Dainippon Pharma
- Taiwan Bio Therapeutics
- Takeda Pharmaceutical
- Teva Pharmaceutical Industries
- Thoratec Corporation
- TiGenix
- Translational Biosciences
- TWO CELLS
- U.S. Stem Cell
- ViaCyte
- VistaGen Therapeutics

Market drivers
- Increase in federal funding in stem cell therapy
- For a full, detailed list, view the full report

Market challenges
- Stringent regulatory environment affecting the product approvals
- For a full, detailed list, view the full report

Market trends
- Evolution of new destinations in the development of stem cell therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • bluebird bio
  • Daiichi Sankyo
  • Kiadis Pharma
  • Pluristem Therapeutics
  • Taiwan Bio Therapeutics
  • MORE
Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction
  • Key market highlights
Part 05: Understanding of stem cell therapy
  • History of stem cell research
Part 06: Ethical issues and regulatory landscape
  • Ethical issues of stem cell research at different phases of research
Part 07: Key clinical trials
  • Attractive clinical trial locations to invest
  • Commercially attractive therapy areas to invest
Part 08: Market landscape
  • Market overview
  • Five forces analysis
Part 09: Market segmentation by therapy
  • Allogeneic stem cell therapy
  • Autologous stem cell therapy
Part 10: Market segmentation by applications
  • Dermatology
  • Musculoskeletal
  • Cardiovascular
Part 11: Geographical segmentation
  • Stem cell therapy market in Americas
  • Stem cell therapy market in EMEA
  • Stem cell therapy market in APAC
Part 12: Market drivers
  • Limitations in traditional organ transplantations fueling the demand for stem cell therapies
  • Increase in federal funding in stem cell therapy
  • Growing demand for personalized medicine
  • Increasing demand to develop effective drugs for cardiology and degenerative disorders
Part 13: Impact of drivers

Part 14: Market challenges
  • Stringent regulatory environment affecting the product approvals
  • Critical ethical challenges with respect to stem cell research
  • High cost of clinical trials and failure rate in clinical trials
Part 15: Impact of drivers and challenges

Part 16: Market trends
  • Evolution of new destinations in the development of stem cell therapies
  • Increasing inorganic growth strategies such as acquisitions and licensing agreements
  • Growing focus on the development of drugs for emerging applications
  • Increasing investments from private enterprises likely to fuel market growth
Part 17: Vendor landscape
  • Competitive scenario
Part 18: Key vendor analysis
  • Holostem Advanced Therapies
  • JCR Pharmaceuticals
  • Organogenesis
  • Osiris Therapeutics
  • Vericel1
  • Other prominent vendors
Part 19: Appendix
  • List of abbreviations
Part 20: About the Author

List of Exhibits

Exhibit 01: Developments in stem cell research
Exhibit 02: Ethical issues faced by various institutes at different phases of cell therapy research
Exhibit 03: Stem cell research policies in Americas
Exhibit 04: Stem cell research policies in EMEA
Exhibit 05: Stem cell research policies in APAC
Exhibit 06: Historical trend of pipeline candidates in different phases
Exhibit 07: Snapshot of pipeline trends in stem cell therapy market
Exhibit 08: Pipeline landscape by therapeutic area 2016
Exhibit 09: Pipeline by development phase 2016
Exhibit 10: Pipeline snapshot in key therapy areas
Exhibit 11: Brief overview of attractive clinical trial locations, therapy areas, and cell types
Exhibit 12: Key clinical trials
Exhibit 13: Global stem cell therapy market snapshot
Exhibit 14: Key marketed products and their company
Exhibit 15: Key vendors with robust Phase III pipeline
Exhibit 16: Global stem cell therapy market 2016-2021 ($ millions)
Exhibit 17: Opportunity analysis in global stem cell therapy market
Exhibit 18: Five forces analysis
Exhibit 19: Global stem cell therapy market segmentation by therapy 2016
Exhibit 20: Global allogeneic stem cell therapy market 2016-2021 ($ millions)
Exhibit 21: Opportunity analysis of allogeneic stem cell therapy market
Exhibit 22: Global autologous stem cell therapy market 2016-2021 ($ millions)
Exhibit 23: Opportunity analysis of autologous stem cell therapy market
Exhibit 24: Global stem cell therapy market segmentation by application 2016
Exhibit 25: Overview of dermatology in stem cell therapy market
Exhibit 26: Overview of musculoskeletal in regenerative medicine market
Exhibit 27: Overview of cardiovascular in stem cell therapy market
Exhibit 28: Segmentation of global stem cell therapy market based on geography 2016 and 2021
Exhibit 29: Stem cell therapy market revenue by geography 2016-2021 ($ millions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Stem cell therapy market in Americas ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: Stem cell therapy market in EMEA ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: Stem cell therapy market in APAC ($ millions)
Exhibit 36: Key stem cell therapy market developments in Japan by global vendors 2015
Exhibit 37: NIH: YoY and growth rate of spending toward stem cell research ($ billions)
Exhibit 38: Breakdown of CIRM funding in various stem cell research funding in 2014 ($ billions)
Exhibit 39: Active programs under CIRM 2014
Exhibit 40: Details of EC funding
Exhibit 41: Impact of drivers
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Regulatory guidelines in Japan
Exhibit 44: Key inorganic growth strategies in global stem cell therapy market
Exhibit 45: Competitive structure analysis of global stem cell therapy market 2016
Exhibit 46: Competitive analysis of global stem cell therapy market
Exhibit 47: Some of the key approvals in global stem cell therapy
Exhibit 48: Strategic success factors of companies in global stem cell therapy market
Exhibit 49: Holostem Advanced Therapies: Key highlights
Exhibit 50: Holostem Advanced Therapies: Strength assessment
Exhibit 51: Holostem Advanced Therapies: Strategy assessment
Exhibit 52: Holostem Advanced Therapies: Opportunity assessment
Exhibit 53: JCR Pharmaceuticals: Strength assessment
Exhibit 54: JCR Pharmaceuticals: Strategy assessment
Exhibit 55: JCR Pharmaceuticals: Opportunity assessment
Exhibit 56: Organogenesis: Key highlights
Exhibit 57: Organogenesis: Strength assessment
Exhibit 58: Organogenesis: Strategy assessment
Exhibit 59: Organogenesis: Opportunity assessment
Exhibit 60: Osiris Therapeutics: Key highlights
Exhibit 61: Osiris Therapeutics: Strength assessment
Exhibit 62: Osiris Therapeutics: Strategy assessment
Exhibit 63: Osiris Therapeutics: Opportunity assessment
Exhibit 64: Vericel: Key highlights
Exhibit 65: Vericel: Strength assessment
Exhibit 66: Vericel: Strategy assessment
Exhibit 67: Vericel: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • bluebird bio
  • Daiichi Sankyo
  • Kiadis Pharma
  • Pluristem Therapeutics
  • Taiwan Bio Therapeutics
  • MORE
New Report Released: - Global Stem Cell Therapy Market 2017-2021

The author of the report recognizes the following companies as the key players in the global stem cell therapy market: Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis, Osiris Therapeutics, and Vericel.

Other Prominent Vendors in the market are: AbbVie, American CryoStem, AM-Pharma, Anterogen, apceth Biopharma, Astellas Pharma, Athersys, Baxter International, Beike Biotechnology, BIOTIME, bluebird bio, Bristol-Myers Squibb, BrainStorm Cell Therapeutics, Brainxell, Caladrius Biosciences, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, Citospin, Corestem, Cytori Therapeutics, Daiichi Sankyo, Fujifilm, Gamida Cell, Global Stem Cells Group, Grupo Ferrer Internacional, GlaxoSmithKline, Hemostemix, Histocell, International Stem Cell, Ivy Institute of Stem Cells, Japan Regenerative Medicine, Kangstem Biotech, Kiadis Pharma, Laboratorios Salvat, MEDIPOST, Mesoblast, Nuo Therapeutics, Opsis Therapeutics, Osiris Therapeutics, Pharmicell, Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics, ReNeuron, RHEACELL, Salus Medical Solutions, Sangamo Therapeutics, Shire, Steminent Biotherapeutics, Sumitomo Dainippon Pharma, Taiwan Bio Therapeutics, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Thoratec Corporation, TiGenix, Translational Biosciences, TWO CELLS, U.S. Stem Cell, ViaCyte, and VistaGen Therapeutics.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.”

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Further, the report states that one of the major factors hindering the growth of this market is stringent regulatory environment affecting the product approvals. Gaining regulatory approval is often difficult, unpredictable, and subjective. Stem cell therapy must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy. However, many individuals visit doctors for transplantation of cell therapy or stem cell implants that are not approved by regulatory bodies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Holostem Advanced Therapies
  • JCR Pharmaceuticals
  • Organogenesis
  • Osiris Therapeutics
  • Vericel
  • AbbVie
  • American CryoStem
  • AM-Pharma
  • Anterogen
  • apceth Biopharma
  • Astellas Pharma
  • Athersys
  • Baxter International
  • Beike Biotechnology
  • BIOTIME
  • bluebird bio
  • Bristol-Myers Squibb
  • BrainStorm Cell Therapeutics
  • Brainxell
  • Caladrius Biosciences
  • Cellular Biomedicine Group
  • Cellular Dynamics International (a subsidiary of Fujifilm)
  • Cesca Therapeutics
  • CHA Biotech
  • Chugai Pharmaceutical
  • Citospin
  • Corestem
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Fujifilm
  • Gamida Cell
  • Global Stem Cells Group
  • Grupo Ferrer Internacional
  • GlaxoSmithKline
  • Hemostemix
  • Histocell
  • International Stem Cell
  • Ivy Institute of Stem Cells
  • Japan Regenerative Medicine
  • Kangstem Biotech
  • Kiadis Pharma
  • Laboratorios Salvat
  • MEDIPOST
  • Mesoblast
  • Nuo Therapeutics
  • Opsis Therapeutics
  • Osiris Therapeutics
  • Pharmicell
  • Pluristem Therapeutics
  • Promethera Biosciences
  • Q Therapeutics
  • ReNeuron
  • RHEACELL
  • Salus Medical Solutions
  • Sangamo Therapeutics
  • Shire
  • Steminent Biotherapeutics
  • Sumitomo Dainippon Pharma
  • Taiwan Bio Therapeutics
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
  • Thoratec Corporation
  • TiGenix
  • Translational Biosciences
  • TWO CELLS
  • U.S. Stem Cell
  • ViaCyte
  • VistaGen Therapeutics
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll